Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays » 06:15
06/23/20
06/23
06:15
06/23/20
06:15
JAZZ

Jazz Pharmaceuticals

$112.85 /

-1.15 (-1.01%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad raised the firm's price target on Jazz Pharmaceuticals to $195 from $183 and keeps an Overweight rating on the shares after hosting a chat with management. The analyst believes Zepzelca is "on the rise" and incorporated the drug into the model.

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$112.85 /

-1.15 (-1.01%)

JAZZ Jazz Pharmaceuticals
$112.85 /

-1.15 (-1.01%)

06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
JAZZ Jazz Pharmaceuticals
$112.85 /

-1.15 (-1.01%)

JAZZ Jazz Pharmaceuticals
$112.85 /

-1.15 (-1.01%)

Hot Stocks
Jazz reports lawsuits filed related to Xyrem, says allegations 'meritless' » 08:23
06/22/20
06/22
08:23
06/22/20
08:23
JAZZ

Jazz Pharmaceuticals

$114.00 /

+3.225 (+2.91%)

In a regulatory filing,…

In a regulatory filing, Jazz Pharmaceuticals reported that on June 17, 2020, a class action lawsuit was filed in the United States District Court in the Northern District of Illinois by Blue Cross and Blue Shield Association, in its capacity as the carrier for the service benefit plan, a/k/a the "Federal Employee Program," a Federal Employee Health Benefits Act Plan, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited and certain other defendant companies, Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth, Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceuticals, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc. On June 18, 2020, two additional lawsuits were filed in the Northern District of California by (i) the New York State Teamsters Council Health and Hospital Fund against the BCBSA Related Defendants and (ii) The City of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and certain other defendant companies, Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc. "The plaintiffs in the BCBSA Lawsuit and New York State Teamsters Lawsuit are seeking to represent a class of direct purchasers, and the plaintiffs in the City of Providence Lawsuit are seeking to represent a class of indirect purchasers. The lawsuits generally allege violations of U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the company's conduct related to its product, Xyrem oral solution, including actions leading up to, and entering into, patent litigation settlements with the BCBSA Related Defendants and the City of Providence Related Defendants, seeking monetary damages, declaratory and injunctive relief against the alleged unlawful conduct, disgorgement of profits and restitution. It is possible that additional lawsuits will be filed against the company making similar or related allegations. While the company believes the allegations to be meritless and intends to defend these lawsuits vigorously, there can be no assurance as to the ultimate outcome of these and any other related lawsuits, which in any event may be costly and time-consuming to defend," the filing stated.

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$114.00 /

+3.225 (+2.91%)

JAZZ Jazz Pharmaceuticals
$114.00 /

+3.225 (+2.91%)

06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
JAZZ Jazz Pharmaceuticals
$114.00 /

+3.225 (+2.91%)

JAZZ Jazz Pharmaceuticals
$114.00 /

+3.225 (+2.91%)

Conference/Events
Jazz Pharmaceuticals to host conference call » 18:00
06/17/20
06/17
18:00
06/17/20
18:00
JAZZ

Jazz Pharmaceuticals

$110.56 /

-0.98 (-0.88%)

Conference call to…

Conference call to discuss the FDA accelerated approval of Zepzelca (lurbinectedin) for treatment of Metastatic Small Cell Lung Cancer will be held on June 17 at 6:15 pm. Webcast Link

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$110.56 /

-0.98 (-0.88%)

JAZZ Jazz Pharmaceuticals
$110.56 /

-0.98 (-0.88%)

06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
JAZZ Jazz Pharmaceuticals
$110.56 /

-0.98 (-0.88%)

JAZZ Jazz Pharmaceuticals
$110.56 /

-0.98 (-0.88%)

Conference/Events
Jazz Pharmaceuticals to host conference call » 04:55
06/17/20
06/17
04:55
06/17/20
04:55
JAZZ

Jazz Pharmaceuticals

$111.54 /

+0.55 (+0.50%)

Conference call to…

Conference call to discuss the FDA accelerated approval of Zepzelca (lurbinectedin) for treatment of Metastatic Small Cell Lung Cancer will be held on June 17 at 6:15 pm. Webcast Link

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$111.54 /

+0.55 (+0.50%)

JAZZ Jazz Pharmaceuticals
$111.54 /

+0.55 (+0.50%)

06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
JAZZ Jazz Pharmaceuticals
$111.54 /

+0.55 (+0.50%)

JAZZ Jazz Pharmaceuticals
$111.54 /

+0.55 (+0.50%)

Conference/Events
Jazz Pharmaceuticals to host conference call » 16:39
06/16/20
06/16
16:39
06/16/20
16:39
JAZZ

Jazz Pharmaceuticals

$111.52 /

+0.53 (+0.48%)

Conference call to…

Conference call to discuss the FDA accelerated approval of Zepzelca (lurbinectedin) for treatment of Metastatic Small Cell Lung Cancer will be held on June 17 at 6:15 pm. Webcast Link

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$111.52 /

+0.53 (+0.48%)

JAZZ Jazz Pharmaceuticals
$111.52 /

+0.53 (+0.48%)

06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
JAZZ Jazz Pharmaceuticals
$111.52 /

+0.53 (+0.48%)

JAZZ Jazz Pharmaceuticals
$111.52 /

+0.53 (+0.48%)

Hot Stocks
Jazz Pharmaceuticals announces FDA accelerated approval of Zepzelca » 15:37
06/15/20
06/15
15:37
06/15/20
15:37
JAZZ

Jazz Pharmaceuticals

$110.01 /

+5.35 (+5.11%)

Jazz Pharmaceuticals…

Jazz Pharmaceuticals announced along with its partner PharmaMar, that the U.S. FDA approved Zepzelca for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. Zepzelca was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Zepzelca will be commercially available in the U.S. in early July. As previously announced in December 2019, PharmaMar and Jazz entered into an exclusive license agreement, which became effective in January 2020, granting Jazz U.S. commercialization rights to Zepzelca.

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$110.01 /

+5.35 (+5.11%)

JAZZ Jazz Pharmaceuticals
$110.01 /

+5.35 (+5.11%)

06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
JAZZ Jazz Pharmaceuticals
$110.01 /

+5.35 (+5.11%)

JAZZ Jazz Pharmaceuticals
$110.01 /

+5.35 (+5.11%)

Over a month ago
On The Fly
Fly Insider: Dynavax, SmartFinancial among weeks notable insider trades » 13:36
06/01/20
06/01
13:36
06/01/20
13:36
DVAX

Dynavax

$7.30 /

+1.18 (+19.28%)

, GDOT

Green Dot

$39.60 /

+1.36 (+3.56%)

, JAZZ

Jazz Pharmaceuticals

$119.65 /

+0.33 (+0.28%)

, RCL

Royal Caribbean

$54.94 /

+3.035 (+5.85%)

, CAR

Avis Budget

$23.39 /

+1.84 (+8.54%)

, SMBK

SmartFinancial

$15.00 /

-0.33 (-2.15%)

, AVTR

Avantor

$18.32 /

-0.68 (-3.58%)

, MRNA

Moderna

$61.79 /

+0.34 (+0.55%)

, BBY

Best Buy

$77.62 /

-0.5 (-0.64%)

, NVDA

Nvidia

$352.16 /

-1.49 (-0.42%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
SMBK SmartFinancial
$15.00 /

-0.33 (-2.15%)

RCL Royal Caribbean
$54.94 /

+3.035 (+5.85%)

NVDA Nvidia
$352.16 /

-1.49 (-0.42%)

MRNA Moderna
$61.79 /

+0.34 (+0.55%)

JAZZ Jazz Pharmaceuticals
$119.65 /

+0.33 (+0.28%)

GDOT Green Dot
$39.60 /

+1.36 (+3.56%)

DVAX Dynavax
$7.30 /

+1.18 (+19.28%)

CAR Avis Budget
$23.39 /

+1.84 (+8.54%)

BBY Best Buy
$77.62 /

-0.5 (-0.64%)

AVTR Avantor
$18.32 /

-0.68 (-3.58%)

DVAX Dynavax
$7.30 /

+1.18 (+19.28%)

05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
GDOT Green Dot
$39.60 /

+1.36 (+3.56%)

05/20/20 Northland
Green Dot price target raised to $42 from $35 at Northland
05/12/20 SunTrust
Green Dot price target raised to $50 from $40 at SunTrust
05/12/20 Craig-Hallum
Green Dot price target raised to $42 from $35 at Craig-Hallum
05/12/20 Needham
Green Dot price target raised to $40 from $30 at Needham
JAZZ Jazz Pharmaceuticals
$119.65 /

+0.33 (+0.28%)

06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
RCL Royal Caribbean
$54.94 /

+3.035 (+5.85%)

05/28/20 Stifel
Royal Caribbean price target raised to $62 from $52 at Stifel
05/21/20
Fly Intel: Top five analyst initiations
05/21/20 JPMorgan
Royal Caribbean price target lowered to $50 from $55 at JPMorgan
05/21/20 Deutsche Bank
Royal Caribbean price target lowered to $36 from $38 at Deutsche Bank
CAR Avis Budget
$23.39 /

+1.84 (+8.54%)

05/21/20
Fly Intel: Top five analyst upgrades
05/21/20 Morgan Stanley
Morgan Stanley ups Avis Budget to Equal Weight after capital raise, cost cuts
05/21/20 Morgan Stanley
Avis Budget upgraded to Equal Weight from Underweight at Morgan Stanley
05/06/20 Deutsche Bank
Avis Budget price target lowered to $16 from $18 at Deutsche Bank
SMBK SmartFinancial
$15.00 /

-0.33 (-2.15%)

11/04/19 DA Davidson
SmartFinancial upgraded to Buy from Neutral at DA Davidson
07/29/19 Raymond James
Raymond James downgrades SmartFinancial to Market Perform on valuation
07/29/19 Raymond James
SmartFinancial downgraded to Market Perform from Outperform at Raymond James
07/10/19 DA Davidson
SmartFinancial initiated with a Neutral at DA Davidson
AVTR Avantor
$18.32 /

-0.68 (-3.58%)

03/16/20 Cowen
Avantor should be bought soon if not now, says Cowen
03/13/20 JPMorgan
Avantor selloff yesterday brings entry point, says JPMorgan
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
02/07/20 Cowen
Avantor weakness a buying opportunity, says Cowen
MRNA Moderna
$61.79 /

+0.34 (+0.55%)

06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/20/20 Morgan Stanley
Moderna price target raised to $90 from $37 at Morgan Stanley
05/19/20 Piper Sandler
Piper trims Moderna target to $100 on capital raise dilution
BBY Best Buy
$77.62 /

-0.5 (-0.64%)

05/22/20 Loop Capital
Best Buy price target raised to $90 from $80 at Loop Capital
05/22/20 Morgan Stanley
Best Buy price target raised to $85 from $75 at Morgan Stanley
05/18/20
Fly Intel: Top five analyst upgrades
05/18/20 Telsey Advisory
Best Buy upgraded to Outperform from Market Perform at Telsey Advisory
NVDA Nvidia
$352.16 /

-1.49 (-0.42%)

05/22/20 JPMorgan
Nvidia price target raised to $405 from $305 at JPMorgan
05/22/20 Rosenblatt
Nvidia price target raised to $400 from $340 at Rosenblatt
05/22/20 Raymond James
Nvidia price target raised to $370 from $330 at Raymond James
05/22/20 Craig-Hallum
Nvidia price target raised to $335 from $300 at Craig-Hallum
SMBK SmartFinancial
$15.00 /

-0.33 (-2.15%)

RCL Royal Caribbean
$54.94 /

+3.035 (+5.85%)

NVDA Nvidia
$352.16 /

-1.49 (-0.42%)

MRNA Moderna
$61.79 /

+0.34 (+0.55%)

JAZZ Jazz Pharmaceuticals
$119.65 /

+0.33 (+0.28%)

GDOT Green Dot
$39.60 /

+1.36 (+3.56%)

DVAX Dynavax
$7.30 /

+1.18 (+19.28%)

CAR Avis Budget
$23.39 /

+1.84 (+8.54%)

BBY Best Buy
$77.62 /

-0.5 (-0.64%)

AVTR Avantor
$18.32 /

-0.68 (-3.58%)

RCL Royal Caribbean
$54.94 /

+3.035 (+5.85%)

NVDA Nvidia
$352.16 /

-1.49 (-0.42%)

MRNA Moderna
$61.79 /

+0.34 (+0.55%)

CAR Avis Budget
$23.39 /

+1.84 (+8.54%)

BBY Best Buy
$77.62 /

-0.5 (-0.64%)

RCL Royal Caribbean
$54.94 /

+3.035 (+5.85%)

NVDA Nvidia
$352.16 /

-1.49 (-0.42%)

MRNA Moderna
$61.79 /

+0.34 (+0.55%)

JAZZ Jazz Pharmaceuticals
$119.65 /

+0.33 (+0.28%)

GDOT Green Dot
$39.60 /

+1.36 (+3.56%)

DVAX Dynavax
$7.30 /

+1.18 (+19.28%)

CAR Avis Budget
$23.39 /

+1.84 (+8.54%)

BBY Best Buy
$77.62 /

-0.5 (-0.64%)

RCL Royal Caribbean
$54.94 /

+3.035 (+5.85%)

NVDA Nvidia
$352.16 /

-1.49 (-0.42%)

MRNA Moderna
$61.79 /

+0.34 (+0.55%)

DVAX Dynavax
$7.30 /

+1.18 (+19.28%)

CAR Avis Budget
$23.39 /

+1.84 (+8.54%)

BBY Best Buy
$77.62 /

-0.5 (-0.64%)

Recommendations
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink » 08:48
06/01/20
06/01
08:48
06/01/20
08:48
JAZZ

Jazz Pharmaceuticals

$119.32 /

+0.2 (+0.17%)

SVB Leerink analyst Ami…

SVB Leerink analyst Ami Fadia raised the firm's price target on Jazz Pharmaceuticals to $169 from $160 o reflect higher sales for lurbinectedin, while keeping an Outperform rating on the shares. Based on a statistical simulation analysis of the upcoming ATLANTIS trial readout in 2L SCLC, the analyst believes the trial has a high likelihood of success in the 84%-98% range. Fadia sees the trial readout in the second half of 2020 as a significant catalyst for Jazz.

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$119.32 /

+0.2 (+0.17%)

JAZZ Jazz Pharmaceuticals
$119.32 /

+0.2 (+0.17%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
JAZZ Jazz Pharmaceuticals
$119.32 /

+0.2 (+0.17%)

JAZZ Jazz Pharmaceuticals
$119.32 /

+0.2 (+0.17%)

Hot Stocks
Jazz Pharmaceuticals board member buys 50K shares of common stock » 18:40
05/27/20
05/27
18:40
05/27/20
18:40
JAZZ

Jazz Pharmaceuticals

$113.38 /

+4.03 (+3.69%)

In a regulatory filing,…

In a regulatory filing, Jazz Pharmaceuticals disclosed that its board member Seamus Mulligan bought 50K shares of common stock on May 25th-26th in a total transaction size of $5.55M.

ShowHide Related Items >><<
JAZZ Jazz Pharmaceuticals
$113.38 /

+4.03 (+3.69%)

JAZZ Jazz Pharmaceuticals
$113.38 /

+4.03 (+3.69%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
JAZZ Jazz Pharmaceuticals
$113.38 /

+4.03 (+3.69%)

JAZZ Jazz Pharmaceuticals
$113.38 /

+4.03 (+3.69%)

Conference/Events
RBC Capital to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
ADUS

Addus HomeCare

$89.04 /

-0.89 (-0.99%)

, HOOK

Hookipa Pharma

$9.27 /

-0.88 (-8.67%)

, KPTI

Karyopharm

$17.68 /

-0.97 (-5.20%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, ENTA

Enanta

$54.33 /

-3.25 (-5.64%)

, REGN

Regeneron

$557.61 /

-1.76 (-0.31%)

, ARAV

Aravive

$12.27 /

-0.31 (-2.46%)

, IMGN

ImmunoGen

$4.62 /

-0.14 (-2.94%)

, HCA

HCA Healthcare

$103.94 /

-1.63 (-1.54%)

, PFE

Pfizer

$37.68 /

-0.4 (-1.05%)

, BCEL

Atreca

$18.06 /

-0.69 (-3.68%)

, JAZZ

Jazz Pharmaceuticals

$113.07 /

-3.23 (-2.78%)

, OVID

Ovid Therapeutics

$4.46 /

+0.29 (+6.95%)

, ACAD

Acadia

$51.02 /

-1.05 (-2.02%)

, BMRN

BioMarin

$93.88 /

-1.46 (-1.53%)

, EHTH

eHealth

$124.65 /

-2.38 (-1.87%)

, EXEL

Exelixis

$24.87 /

-0.79 (-3.08%)

, INO

Inovio

$14.56 /

+0.41 (+2.90%)

, SPRT

Support.com

$1.25 /

-0.01 (-0.79%)

, CYH

Community Health

$3.11 /

-0.05 (-1.58%)

, INCY

Incyte

$94.92 /

-1.58 (-1.64%)

, AGIO

Agios Pharmaceuticals

$47.89 /

-0.93 (-1.90%)

, EGRX

Eagle Pharmaceuticals

$53.24 /

-1.26 (-2.31%)

, IGMS

IGM Biosciences

$52.75 /

-2.66 (-4.80%)

, AIMT

Aimmune

$16.55 /

-0.92 (-5.27%)

, VRCA

Verrica Pharmaceuticals

$10.11 /

-0.62 (-5.78%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$54.33 /

-3.25 (-5.64%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$557.61 /

-1.76 (-0.31%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
ARAV Aravive
$12.27 /

-0.31 (-2.46%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$37.68 /

-0.4 (-1.05%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.06 /

-0.69 (-3.68%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$51.02 /

-1.05 (-2.02%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$124.65 /

-2.38 (-1.87%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.56 /

+0.41 (+2.90%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.25 /

-0.01 (-0.79%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$94.92 /

-1.58 (-1.64%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.